GASTROINTESTINAL TUMOURS, COLORECTAL

Phase III RECOURSE trial of TAS-102 vs. placebo, with best supportive care (BSC), in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies

E. Van Cutsem